Our team together with scientists of the Biological Faculty of Moscow State University and Institute of Molecular Genetics has developed a new drug “Longolytin” for the treatment of thrombotic complications of cardiovascular diseases.

The basis of the drug is the active substance longolytin – a complex of thrombolytic and fibrinolytic enzymes secreted by the microscopic fungus Arthrobotrys Longa. Numerous studies have shown that longolytin quickly and effectively resolves blood clots, helping to restore blood flow in the vascular bed.

The developed drug is a gel for external use, which can be used for superficial thrombosis, thrombophlebitis and other complications of cardiovascular diseases.

Currently, preclinical studies have been completed, including toxicology, pharmacology and pharmacokinetics of the drug “Longolytin”. Studies have shown its safety and effectiveness, which was higher than that of existing heparin-containing drugs. The drug is non-toxic, does not cause allergic or immune reactions of the body.